key: cord-0303494-1q4btjl8
authors: Brant-Zawadzki, M.; Fridman, D.; Robinson, P. A.; German, R.; Shapiro, A.; Breit, M.; Wilton, S.; Burke, E.; Bock, J.; Hara, J.
title: Longevity of SARS-CoV-2 Antibody in Health Care Workers: 6-Months Follow Up
date: 2021-08-26
journal: nan
DOI: 10.1101/2021.08.25.21262632
sha: babcfc85630fa02dd2e6680be550c4d960613616
doc_id: 303494
cord_uid: 1q4btjl8

The prevalence and longevity of acquired immunity to coronavirus disease 2019 (COVID-19) in health care workers (HCWs) is of great interest, especially with the roll-out of vaccines for SARS-CoV-2. Determining such immunity may enhance knowledge about susceptibility of HCWs to COVID-19, frequency of vaccine administration, and degree of workplace risk, and may also support enactment of better workplace policies and procedures. The present study reports on 6-months follow-up serosurveillance to determine the longevity of SARS-CoV-2 antibodies in HCWs. Sub-sample (n=35) of the original serosurveillance in HCWs (n = 3,458) with baseline, 8-week, and 6-month blood sampling were analyzed. Information on job duties, location, COVID-19 symptoms, polymerase chain reaction test history, travel since January 2020, and household contacts with COVID-19 was collected. Of 35 subjects, 13 were seropositive at baseline and maintained positivity at 8-week follow-up, with 3 losing positivity at 6-month follow-up. Among 22 subjects who were seronegative at baseline and seropositive at 8-week follow-up, all but one maintained positivity at 6-month follow-up. There was no significant effect of all factors (e.g., age, gender, job duties) examined at the .05 level on seropositivity at 6-month follow-up. The observed antibody longevity was 7.0+/-0.6 months for seropositive subjects (n=13), and 4.5+/-0.8 months for those seronegative subjects (n=22), at baseline. The longest duration of seropositivity observed in this cohort was 7.9 months (236 days). With reported COVID-19-related symptoms up to 4.7 months prior to baseline blood sampling, possibly longer antibody presence is suggested. Similarly, seropositivity at 6-month follow-up further suggests greater antibody longevity than observed in this study.

The prevalence and longevity of acquired immunity to coronavirus disease 2019 (COVID-19) in health care workers (HCWs) is of great interest, especially with the roll-out of vaccines for SARS-CoV-2. Determining such immunity may enhance knowledge about susceptibility of HCWs to COVID-19, frequency of vaccine administration, and degree of workplace risk, and may also support enactment of better workplace policies and procedures.

Prior sero-suvaillance studies among HCWs have reported widely ranging antibody prevalence from 89.3% in Wuhan, China (n=424) [1] , 35.8% in New York City (n=285) [2] , to 7.4% in Milan, Italy [3] , and 2.67% in Denmark (n=28,792) [4] . Our previous HCW sero-suvaillance studies have shown a low prevalence of antibodies ranging from 0.98% to 2.58% depending on sampling timing (e.g., before or after partial state re-opening in late May, 2020) [5, 6] . Serology prevalence in HCWs was found to be loosely correlated with community prevalence [6] .

The longevity of antibody presence has also been reported, though sparsely, with varying range among HCWs [7] [8] [9] . This study reports 6-month follow-up serosurveillance conducted on subsamples from our HCW cohort studied in May through August, 2020, at Hoag Memorial Hospital Presbyterian, California, United States.

IRB approval was obtained for this study (Providence St. Joseph Health IRB # 2020000337). The original HCWs cohort (n=3,458) was recruited by email notification to the entire employee workforce and medical staff [6] . Consenting participants were interviewed with regards to job duties, location, COVID-19 symptoms (i.e., fever, sore throat, cough, rhinorrhea, loss of taste or smell), PCR test history, travel record, and existence of household contacts with COVID-19. Job duties were used to further classify subjects into high (e.g., MD, RN, ICU tech), medium (e.g., phlebotomist, medical tech), or low (e.g., admin, IT) risk groups to stratify levels of direct exposure to COVID-19. A blood sample (~5ml) was collected at enrollment and 8-week followup, from each subject for serum analysis for IgG antibodies to SARS-CoV-2 using the VITROS Anti-SARS-CoV-2 IgG Reagent Pack and Calibrator on the VITROS® XT 7600 instrument by Ortho Clinical Diagnostics approved for the FDA emergency use authorization.

Additional blood samples were collected at 6-month follow-up from those who had positive antibody results at the initial and 8-week follow-up, or at 8-week follow-up only, with a total of 96 subjects eligible. However, due to the COVID-19 vaccine roll-out around the time of 6-month follow-up, with some subjects already vaccinated by the time of their blood sampling, 61 subjects were excluded from analysis, resulting in 35 subjects (36%) included in this study. The study was discontinued after January 24, 2021.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 26, 2021. ; https://doi.org/10.1101/2021.08.25.21262632 doi: medRxiv preprint Analysis A Mann-Whitney U test was used to assess the significance of age, and a series of one-sided Fisher's exact tests were used for gender, race, and job risk level, on seropositivity at 6-month follow-up. Longevity of antibody positivity was plotted for each subject along with a selfreported polymerase chain reaction (PCR) test history, onset of COVID-19 related symptoms, prior travel record, close contract with COVID-19 patients, and rank-ordered by baseline antibody results, and then job risk levels. Table 1 summarizes sample characteristics (n=35). Of 35 subjects, 13 were seropositive at baseline and maintained positivity at 8-week follow-up, with 3 losing positivity at 6-month follow-up. Among 22 subjects who were seronegative at baseline and seropositive at 8-week follow-up, all but one maintained positivity at 6-month follow-up. A Mann-Whitney U test and Fisher's exact tests showed no significant effect of all factors examined at the .05 level on seropositivity at 6-month follow-up. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 26, 2021. ; https://doi.org/10.1101/2021.08.25.21262632 doi: medRxiv preprint Figure 1 shows longevity of antibody positivity, demonstrating 7.0+/-0.6 months of longevity for seropositive subjects (n=13), and 4.5+/-0.8 months for those seronegative subjects (n=22), at baseline. The longest duration of seropositivity observed in this cohort was 7.9 months (236 days). 

Our data suggests antibody longevity of up to 7.9 months, with possibly greater longevity, in our HCWs. This finding corroborates other antibody longevity studies reporting greater longevity than previously observed in mixed cohort of patients, HCWs, and general public [10] [11] [12] , up to 8 months of longevity [11] .

Among those seropositive at baseline, eight reported COVID-19-related symptoms up to 4.7 months prior to baseline blood sampling, suggesting possibly longer antibody presence. Similarly, the fact that all seropositive cases except four maintained seropositvity at 6 months, further suggests greater antibody longevity than observed in this study.

This finding is encouraging for both those with acquired immunity from subclinical infection, and those who would acquire immunity by vaccination. A study from the National Cancer Institute reports that people with positive antibodies have substantial immunity to SARS-CoV-2, which means they may be at lower risk for future infection [13] . It is not known whether waning . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted August 26, 2021. ; https://doi.org/10.1101/2021.08.25.21262632 doi: medRxiv preprint antibody presence equates to a loss of T-cell based immunity. Our findings may help guide prioritization of HCWs for immunization based on their serology history.

Factors associated with asymptomatic infection in healthcare workers with SARS-CoV-2 infection in Wuhan, China: a multi-center retrospective cohort study

Prevalence of SARS-CoV-2 Antibodies Among Healthcare Workers at a Tertiary Academic Hospital in New York City

SARS-CoV-2 specific serological pattern in healthcare workers of an Italian COVID-19 forefront hospital

Risk of COVID-19 in health-care workers in Denmark: an observational cohort study

SARS-CoV-2 antibody prevalence in health care workers: Preliminary report of a single center study

Prevalence and Longevity of SARS-CoV-2 Antibodies Among Healthcare Workers, Open Forum Infectious Diseases. ofab015

Change in Antibodies to SARS-CoV-2 Over 60 Days Among Health Care Personnel in

Antibodies to SARS-CoV-2 are associated with protection against reinfection

Health Workers' Antibody Levels Wane After SARS-CoV-2 Infection

Robust neutralizing antibodies to SARS-CoV-2 infection persist for months

Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans

Seroprevalence of anti-SARS-CoV-2 antibodies in COVID-19 patients and healthy volunteers up to 6 months post disease onset

Association of SARS-CoV-2 Seropositive Antibody Test With Risk of Future Infection

We acknowledge our healthcare workers who have contributed to this study.